AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 28 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $13,754 | -65.6% | 30,572 | -59.7% | 0.00% | – |
Q3 2022 | $40,000 | -70.8% | 75,875 | -72.0% | 0.00% | – |
Q2 2022 | $137,000 | -18.9% | 271,395 | +269.7% | 0.00% | – |
Q1 2022 | $169,000 | +11.9% | 73,414 | +131.6% | 0.00% | – |
Q4 2021 | $151,000 | +86.4% | 31,700 | +210.8% | 0.00% | – |
Q3 2021 | $81,000 | -70.2% | 10,200 | -73.9% | 0.00% | – |
Q2 2021 | $272,000 | -18.8% | 39,100 | -7.6% | 0.00% | – |
Q1 2021 | $335,000 | -58.9% | 42,300 | -59.2% | 0.00% | – |
Q4 2020 | $816,000 | +142.1% | 103,718 | +118.2% | 0.00% | – |
Q3 2020 | $337,000 | +29.1% | 47,524 | +68.9% | 0.00% | – |
Q2 2020 | $261,000 | +137.3% | 28,143 | +18.8% | 0.00% | – |
Q1 2020 | $110,000 | -0.9% | 23,690 | +63.3% | 0.00% | – |
Q4 2019 | $111,000 | -45.3% | 14,505 | -51.2% | 0.00% | – |
Q2 2019 | $203,000 | -78.9% | 29,729 | -75.1% | 0.00% | – |
Q1 2019 | $960,000 | +1448.4% | 119,191 | +826.9% | 0.00% | – |
Q2 2016 | $62,000 | – | 12,859 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Yu Fan | 112,044 | $532,000 | 6.17% |
Aisling Capital Management LP | 1,691,151 | $8,033,000 | 2.83% |
Bain Capital Life Sciences Investors, LLC | 2,847,689 | $13,527,000 | 1.07% |
GREAT POINT PARTNERS LLC | 910,251 | $4,324,000 | 0.96% |
Samsara BioCapital, LLC | 883,720 | $4,198,000 | 0.81% |
Sio Capital Management, LLC | 498,500 | $2,368,000 | 0.71% |
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,167,000 | 0.53% |
Nantahala Capital Management | 2,813,560 | $13,364,000 | 0.47% |
Altium Capital Management LP | 293,764 | $1,395,000 | 0.38% |
Lion Point Capital, LP | 300,000 | $1,425,000 | 0.38% |